Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9959324 | 0.84 | LTA4H (0.51) | SMPD1NPC1RAB9ACYP4F2CYP4A11 | |
| SCHEMBL13520120 | 0.83 | NOTUM (0.51) | SMPD1NOTUMNPC1RAB9ABRD4 | |
| SCHEMBL15684128 | 0.83 | SMPD1 (0.47) | SMPD1NPC1RAB9ABRD4 | |
| SCHEMBL12268217 | 0.83 | SMPD1 (0.47) | SMPD1NPC1RAB9ABRD4 | |
| SCHEMBL17409116 | 0.83 | SMPD1 (0.47) | SMPD1NPC1RAB9ABRD4 | |
| SCHEMBL25025302 | 0.83 | SMPD1 (0.47) | SMPD1NPC1RAB9ABRD4 | |
| SCHEMBL17726200 | 0.83 | SMPD1 (0.53) | SMPD1 | |
| SCHEMBL14699907 | 0.81 | PDE2A (0.46) | SMPD1NPC1RAB9A | |
| SCHEMBL24578981 | 0.81 | MEN1 (0.44) | SMPD1NPC1RAB9ABRD4 | |
| SCHEMBL20860385 | 0.80 | SMPD1 (0.44) | SMPD1NPC1RAB9ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250163020-A1 | Chiral Synthesis of Nornicotine and Nicotine | SIEGFRIED AG (CH) | 2025-05-22 | — | — | US | disclosed |
| EP-4540239-A1 | CHIRAL SYNTHESIS OF NORNICOTINE AND NICOTINE | Siegfried AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| EP-4251620-B1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-04-16 | — | — | EP | disclosed |
| US-12275716-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240188620-A1 | SUPPORTED NICOTINE COMPOSITION | ZANOPRIMA LIFESCIENCES LTD (GB) | 2024-06-13 | — | — | US | disclosed |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| WO-2011076734-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076732-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING GASTROINTESTINAL DISORDERS | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| US-7960559-B2 | Synthesis of enone intermediate | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110009639-A1 | SYNTHESIS OF ENONE INTERMEDIATE | MYERS ANDREW G | 2011-01-13 | — | — | US | disclosed |
| US-20110009371-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| US-7807842-B2 | Synthesis of tetracyclines and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-10-05 | — | — | US | disclosed |
| US-7763735-B2 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-07-27 | — | — | US | disclosed |
| WO-2010066682-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2010-06-17 | — | — | WO | disclosed |
| US-20100130451-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2010-05-27 | — | — | US | disclosed |
| US-20090093640-A1 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | GLP1R, GIPR, SLC5A1 | SMPD1 1961/4885NOTUM 3806/4885NPC1 650/4885 |
| US-20250163020-A1 | Chiral Synthesis of Nornicotine and Nicotine | NNMT, SLC6A12, HNMT | SMPD1 3153/4885NOTUM 357/4885NPC1 4030/4885 |
| US-20110009639-A1 | SYNTHESIS OF ENONE INTERMEDIATE | TECR, ECI1, ERAL1 | SMPD1 4418/4885NOTUM 2493/4885NPC1 2759/4885 |
| US-20090093640-A1 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | TECR, TSN, TARS2 | SMPD1 4683/4885NOTUM 3195/4885NPC1 3921/4885 |
| US-12275716-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | SMPD1 2303/4885NOTUM 2622/4885NPC1 2550/4885 |
| US-20100130451-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | CCNE1, CCNE2, CCNT2 | SMPD1 4492/4885NOTUM 3096/4885NPC1 4214/4885 |
| US-20110009371-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | TET1, TET3, MYC | SMPD1 4444/4885NOTUM 2586/4885NPC1 3339/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | SMPD1 3186/4885NOTUM 4226/4885NPC1 3337/4885 |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | SMPD1 3199/4885NOTUM 3770/4885NPC1 3459/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | SMPD1 4042/4885NOTUM 3807/4885NPC1 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.